Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 541 AL 555

Generation of functional organs from stem cells

Liu Y, Yang R, He Z, Gao WQ.

Cell Regen. 2013 Jan 22;2(1):1. doi: 10.1186/2045-9769-2-1. eCollection 2013.

Mass spectrometry for the detection of potential psychiatric biomarkers

Ngounou Wetie AG, Sokolowska I, Wormwood K, Beglinger K, Michel TM, Thome J, Darie CC, Woods AG.

J Mol Psychiatry. 2013 Jun 5;1(1):8. doi: 10.1186/2049-9256-1-8. eCollection 2013.

Catecholamines and Neurodegeneration in Parkinson's Disease-From Diagnostic Marker to Aggregations of α-Synuclein

Sawada H, Oeda T, Yamamoto K.

Diagnostics (Basel). 2013 Mar 25;3(2):210-21. doi: 10.3390/diagnostics3020210.

Rapid dopamine dynamics in the accumbens core and shell: learning and action

Saddoris MP, Sugam JA, Cacciapaglia F, Carelli RM.

Front Biosci (Elite Ed). 2013 Jan 1;5(1):273-88. doi: 10.2741/e615.

Role of HuD in nervous system function and pathology

Perrone-Bizzozero N, Bird CW.

Front Biosci (Schol Ed). 2013 Jan 1;5(2):554-63. doi: 10.2741/s389.

Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease

Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH.

Eur J Neurol. 2013 Jan;20(1):5-15. doi: 10.1111/j.1468-1331.2012.03866.x.

EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease

Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M.

Eur J Neurol. 2013 Jan;20(1):16-34. doi: 10.1111/ene.12022.

Effective management of lower urinary tract dysfunction in idiopathic Parkinson's disease

Kapoor S, Bourdoumis A, Mambu L, Barua J.

Int J Urol. 2013 Jan;20(1):79-84. doi: 10.1111/j.1442-2042.2012.03220.x.

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results

Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, Lenz RA.

Parkinsonism Relat Disord. 2013 Mar;19(3):339-45. doi: 10.1016/j.parkreldis.2012.11.020. Epub 2013 Jan 1.

Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review

Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, de Bie RM, Deuschl G, Eggert K, Houeto JL, Kulisevsky J, Nyholm D, Odin P, Østergaard K, Poewe W, Pollak P, Rabey JM, Rascol O, Ruzicka E, Samuel M, Speelman H, Sydow O, Valldeoriola F, van der Linden C, Oertel W.

J Neurol. 2013 Nov;260(11):2701-14. doi: 10.1007/s00415-012-6798-6. Epub 2013 Jan 5.

Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease

Taylor JM, Main BS, Crack PJ.

Neurochem Int. 2013 Apr;62(5):803-19. doi: 10.1016/j.neuint.2012.12.016. Epub 2013 Jan 4.

The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats

Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E.

Behav Brain Res. 2013 Apr 15;243:6-15. doi: 10.1016/j.bbr.2012.12.051. Epub 2013 Jan 4.

The interplay between environmental and genetic factors in Parkinson's disease susceptibility: the evidence for pesticides

Dardiotis E, Xiromerisiou G, Hadjichristodoulou C, Tsatsakis AM, Wilks MF, Hadjigeorgiou GM.

Toxicology. 2013 May 10;307:17-23. doi: 10.1016/j.tox.2012.12.016. Epub 2013 Jan 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias